Drugs / 6-tioguanine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04307576 | Jul 2020 → Jun 2033 expected | acute lymphoblastic leukemia | Mats Heyman | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6-tioguanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04307576 ↗ |
| Known as | 6-thioguanine | “with low dose (2.5-12.5 mg/m2/day) oral 6-thioguanine (6TG) (experimental arm)” PMID 35501736 ↗ May 2022 |
| Known as | 6TG | “with low dose (2.5-12.5 mg/m2/day) oral 6-thioguanine (6TG) (experimental arm)” PMID 35501736 ↗ May 2022 |
| Route | Oral | “low dose (2.5-12.5 mg/m2/day) oral 6-thioguanine” PMID 35501736 ↗ May 2022 |